- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05109000
Comparison of Subcutaneous Injection of Normal Saline and Bacteriostatic Saline
Clinical Effects of the Subcutaneous Injection of 10ml of Normal Saline and Bacteriostatic Saline: A Double-Blind Randomized Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Both normal saline and bacteriostatic saline are often used as vehicles for the injection of therapeutic drugs. However, their properties differ slightly as a result of the 0.9% benzyl alcohol component of BS. While benzyl alcohol is known to have local anesthetic properties, it also is an irritant and can cause inflammation at the injection site. In acidic conditions, benzyl alcohol is converted to benzoic acid and benzaldehyde. Objective and prospective data are needed to confirm these characteristics.
The present protocol calls for random allocation of subcutaneous injections of 10 mL of NS into one anterior thigh and 10 mL of BS into the contralateral anterior thigh. Based on the verified safety of up to 30 mL of 0.9% bacteriostatic saline, this volume of saline solution poses little to no risk.
Each thigh will receive one subcutaneous injection of either NS or BS, which will be determined by random allocation. Clinical follow-up examination will be done at 24 hours, 48 hours, and 7 days.
It is expected that by day seven, all signs of inflammation or bruising will have resolved.
Both NS and BS are FDA-approved for subcutaneous injection and are commonly utilized daily by many physicians. A study documenting the benefits and disadvantages of NS and BS has never been done to the investigators' knowledge and will be helpful for medical professionals in determining which type of solution to use in certain circumstances.
The sample size for this study is 32 subjects with a stopping point for analysis after 16 subjects. The sample size must be a multiple of four to satisfy the randomization in groups of four criteria. Investigators are analyzing the t-statistics at a level of alpha = 0.01, considering the Bonferroni correction. If after 16 subjects, statistical significance showing a difference between NS and BS has not been reached, investigators will continue with 16 more subjects.
Tenderness, soreness, and pruritis NPS will be evaluated by paired t-tests to determine if the effects of injection by NS vs. BS differ at each of the four evaluation times. Investigators will do the same for the quantitative data gathered for bruising and redness surface area. This quantitative analysis will result in t-statistics and corresponding P-values which will be evaluated with an alpha = 0.01, considering the Bonferroni correction. For the categorical data for the intensity of bruising and redness/inflammation, investigators will create the categories of none (0), mild (1), moderate (2), and intense (3) and use this data to perform t-tests for significance.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Claire M Richards
- Phone Number: 9493904965
- Email: crichards7899@yahoo.com
Study Locations
-
-
California
-
San Juan Capistrano, California, United States, 92675
- HK Dermatology
-
Contact:
- Claire M Richards
- Phone Number: 949-390-4965
- Email: crichards7899@yahoo.com
-
Principal Investigator:
- Jeffrey A Klein, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All volunteer subjects will be healthy, mature in behavior and temperament, and without mental impairment.
- A volunteer must have signed an informed consent form prior to participation.
- A subject must be at least 16 years of age.
- All subjects must weigh at least 40kg = 88lb.
- All subjects must complete a standard medical history questionnaire.
- All subjects must agree to return for a follow-up examination, 1 day, 2 days, and 1-week post-injections.
Exclusion Criteria:
- Pregnant women are excluded.
- History of an adverse reaction to percutaneous injections, such as fainting and lightheadedness (vasovagal reactions, near syncope).
- Significant needle phobia or anxiety.
- Vasovagal reaction associated with any medical procedures or the sight of blood.
- History of having or having had a blood-born infection with HIV, Hepatitis B, Hepatitis C.
- Evidence of active skin infection.
- Pre-existing or concurrent Infections (cutaneous, urinary, pneumonia are exclusionary).
- History of radiation therapy or surgery involving the area near the proposed injection site.
- Uncontrolled or labile hypertension.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Normal Saline
This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject.
In this arm, the subject will receive a 10 mL subcutaneous injection of normal saline into either their left or right anterior thigh.
The side will be determined by randomization protocol.
|
10 mL subcutaneous injection into one randomized anterior thigh of subject
Other Names:
|
Experimental: Bacteriostatic Saline
This is a randomized, double-blind, single-center clinical trial comparing normal saline and bacteriostatic saline subcutaneous injection within a single subject.
In this arm, the subject will receive a 10 mL subcutaneous injection of bacteriostatic saline into either their left or right anterior thigh.
The side will be determined by randomization protocol.
|
10 mL subcutaneous injection into the contralateral anterior thigh of subject
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Injection Pain
Time Frame: Time Post-Injection: 0 minutes
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 0 minutes
|
Erythema
Time Frame: Time Post-Injection: 5 minutes
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 5 minutes
|
Erythema
Time Frame: Time Post-Injection: 1 hour
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 1 hour
|
Erythema
Time Frame: Time Post-Injection: 24 hours
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 24 hours
|
Erythema
Time Frame: Time Post-Injection: 48 hours
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 48 hours
|
Erythema
Time Frame: Time Post-Injection: 7 days
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 7 days
|
Bruising
Time Frame: Time Post-Injection: 5 minutes
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 5 minutes
|
Bruising
Time Frame: Time Post-Injection: 1 hour
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 1 hour
|
Bruising
Time Frame: Time Post-Injection: 24 hours
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 24 hours
|
Bruising
Time Frame: Time Post-Injection: 48 hours
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 48 hours
|
Bruising
Time Frame: Time Post-Injection: 7 days
|
Intensity by visual objective assessment: none (0), mild (1), moderate (2), intense (3)
|
Time Post-Injection: 7 days
|
Tenderness
Time Frame: Time Post-Injection: 5 minutes
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 5 minutes
|
Tenderness
Time Frame: Time Post-Injection: 1 hour
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 1 hour
|
Tenderness
Time Frame: Time Post-Injection: 24 hours
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 24 hours
|
Tenderness
Time Frame: Time Post-Injection: 48 hours
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 48 hours
|
Tenderness
Time Frame: Time Post-Injection: 7 days
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 7 days
|
Soreness
Time Frame: Time Post-Injection: 5 minutes
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 5 minutes
|
Soreness
Time Frame: Time Post-Injection: 1 hour
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 1 hour
|
Soreness
Time Frame: Time Post-Injection: 24 hours
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 24 hours
|
Soreness
Time Frame: Time Post-Injection: 48 hours
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 48 hours
|
Soreness
Time Frame: Time Post-Injection: 7 days
|
Numerical Pain Score (NPS): 0-10
|
Time Post-Injection: 7 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NS vs. BS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anesthesia, Local
-
Assistance Publique - Hôpitaux de ParisINSERM UMR-942, Paris, France; M3DISIMNot yet recruitingPrediction Models for Cardiovascular and Neurocognitive Disease Risk in the General Population (CME)Anesthesia, Local | AnesthesiaFrance
-
Charite University, Berlin, GermanyCompletedAnesthesia, Local | AnesthesiaGermany
-
Grünenthal GmbHTerminatedAnalgesia | Anesthesia, Local | AnesthesiaNetherlands
-
Charite University, Berlin, GermanyCompletedAnesthesia, Local | Anesthesia | Anesthesia; Adverse EffectGermany
-
Assistance Publique - Hôpitaux de ParisINSERM UMR-942, Paris, France; M3DISIMRecruiting
-
Novocol Pharmaceutical of Canada, Inc.CompletedAnesthesia, Local | Dental Anesthesia | Anesthesia, ReversalUnited States
-
University Health Network, TorontoRecruiting
-
Kfir SiagNot yet recruiting
-
Hams Hamed AbdelrahmanCompleted
-
University of BaghdadActive, not recruiting
Clinical Trials on Sodium Chloride 0.9% Inj
-
BioAegis Therapeutics Inc.Not yet recruitingDecompression Sickness
-
Wroclaw Medical UniversityRecruiting
-
University Hospital Birmingham NHS Foundation TrustUnknownCoronary Artery Bypass SurgeryUnited Kingdom
-
University of East AngliaUnknownVascular Diseases | Coronary Artery Disease | Diabetes Mellitus | Atherosclerosis | Cardiac DiseaseUnited Kingdom
-
Exela Pharma Sciences, LLC.Terminated
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2United States
-
Hospital Universitari Vall d'Hebron Research InstituteCompletedHepatic EncephalopathySpain
-
Oslo University HospitalUniversity of Oslo; Norwegian University of Science and Technology; St. Olavs... and other collaboratorsCompletedMyocardial Infarction | Coronary DiseaseNorway
-
University of EdinburghNHS LothianUnknown